CAMP4 Therapeutics Corporation
NASDAQ:CAMP · NASDAQ Global Market
-$0.03 today
Vol 0.86M · Avg 0.09M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-168.5%
avg -22.6%
ROIC
-50.8%
avg -24.8%
ROA
-68.2%
avg -26.0%
Analysis
ROIC is currently the strongest return metric at -50.8% versus its period average of -24.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joshua Mandel-Brehm | Chief Executive Officer, President & Director | $896,250.00 | — | 43 | $580,000.00 | 2.73% |
Kelly Gold | Chief Financial Officer | $734,691.00 | — | 48 | $215,000.00 | 1.01% |
Yuri Maricich | Chief Medical Officer | $702,000.00 | — | 45 | $215,000.00 | 1.01% |
Richard A. Young | Founder & Independent Director | $146,556.00 | — | 72 | $28,000.00 | 0.13% |
Leonard I. Zon | Founder & Chairman of Scientific Advisory Board | — | — | — | $9,000.00 | 0.04% |
Alla Sigova | Senior Vice President of Platform | — | — | — | — | — |
Caleb Moore | Chief Business Operations Officer | — | — | — | — | — |
Michelle Gates | Senior Vice President & Chief People Officer | — | — | — | — | — |
Daniel Tardiff | Chief Scientific Officer | — | — | 46 | $170,000.00 | 0.80% |
Satya Kuchimanchi | Senior Vice President of Technical Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
9
$8.55M
Sells
0
$0.00
Net Sentiment
+$8.55M
Net buying
Most Active
Polaris Management Co. VII, L.L.C.
2 transactions
Analysis
Insiders reported 9 buys worth $8.55M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $8.55M. Polaris Management Co. VII, L.L.C. was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -32.4% | N/A2 analysts |
| Revenue | N/A | N/A | +15.8% | -15.2% (15yr)2 analysts |
| Net Income | N/A | N/A | -27.6% | N/A2 analysts |
| EBIT | N/A | N/A | +20.7% | N/A2 analysts |
Analysis
Recent growth has been strongest in EBIT at +20.7% over three years. Forward estimates point to Revenue at -15.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
ALX Oncology Holdings Inc.
NASDAQ:ALXO
$212.61M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$155.81M
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Repare Therapeutics Inc.
RPTX
$114.24M
MindWalk Holdings Corp.
NASDAQ:HYFT
$72.87M
Biomea Fusion, Inc.
NASDAQ:BMEA
$69.61M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
aTyr Pharma, Inc.
ATYR
$43.18M
Quince Therapeutics, Inc.
QNCX
$5.20M
Who manages CAMP?
CAMP4 Therapeutics Corporation (CAMP) lists 10 active executives. The top listed executive is Joshua Mandel-Brehm, Chief Executive Officer, President & Director.
Are CAMP insiders buying or selling?
Recent insider activity shows net buying of $30.53M.
Explore More
Continue the stock analysis
Jump to another research area for this company.